Targeting neuroinflammation and ApoE issues in Alzheimer's disease using microRNA therapy
Official title: MicroRNA lipid-nanoparticle based therapy targets neuroinflammation and ApoE dysregulation in Alzheimer’s disease
Funded at University of Kentucky · NIH-11001224 · Data updated 2026-11-12
This study is exploring a new treatment for Alzheimer's disease that uses a tiny molecule called microRNA-223 to help reduce inflammation in the brain, and it could potentially improve thinking and memory for patients if it works well.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kentucky NIH-funded |
| Lab location | 1 site (Lexington, United States) |
| Project start | April 15, 2023 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $600,292 |
| NIH project number | 5R01AG082142-03 |
| Project ID | NIH-11001224 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at risk for developing Alzheimer's-related dementia.
✕Less likely to help
Patients with other forms of dementia or neurological disorders unrelated to Alzheimer's disease may not benefit from this research.
What this research studies
This research investigates the use of microRNA-223, a small regulatory RNA, to address neuroinflammation and ApoE dysregulation in Alzheimer's disease. The approach involves a novel delivery system using lipid nanoparticles to effectively target and modulate the activity of microRNA-223 in brain cells. By focusing on the relationship between microRNA-223 and the inflammatory response in the brain, the research aims to develop a therapeutic strategy that could mitigate the effects of Alzheimer's disease. Patients may benefit from this innovative treatment if it proves effective in reducing neuroinflammation and improving cognitive function.
Why it matters
Potential benefit: If successful, this research could lead to a new therapy that reduces inflammation and improves brain health in Alzheimer's patients.
How similar studies have gone: While microRNA therapies are a novel approach in Alzheimer's treatment, preliminary studies have shown promise in targeting neuroinflammation, suggesting potential for success.
Where this research is happening
-
University of Kentucky
Lexington, United States Active
Researchers
- Principal investigator: Wang, Wang-Xia — University of Kentucky
- Study coordinator: Wang, Wang-Xia
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.